...
首页> 外文期刊>Oncology letters >Clinical significance of the 'not otherwise specified' subtype in candidates for resectable non-small cell lung cancer
【24h】

Clinical significance of the 'not otherwise specified' subtype in candidates for resectable non-small cell lung cancer

机译:可切除的非小细胞肺癌候选人中“未另作说明”亚型的临床意义

获取原文
获取原文并翻译 | 示例

摘要

The histological subtype of non-small-cell lung cancer (NSCLC) is a significant factor when selecting treatment strategies. However, cases are occasionally encountered that are diagnosed as 'not otherwise specified' (NOS) prior to surgery, due to an uncertain histological subtype. The present study investigated the prognostic significance of the NOS subtype for patients with resectable NSCLC. Between 2001 and 2011, 1,913 patients were diagnosed with NSCLC using transbronchial biopsy and underwent surgical resection at two facilities in Japan. Of these patients, 151 (7.9%) were pre-operatively diagnosed with NSCLC-NOS (NOS group) and the remainder had confirmed histological subtypes (confirmed group). The present study compared the clinicopathological features and prognoses of these groups. Analyses of resected specimens revealed that pleomorphic cell carcinoma, large cell neuroendocrine cell carcinoma, large cell carcinoma and adenosquamous carcinoma were significantly more common in the NOS group than in the confirmed group (P<0.001, P=0.002, P=0.019 and P=0.014, respectively). The five-year survival rate was significantly poorer in the NOS group (60.5 vs. 67.1%; P=0.010), particularly for stage I disease (70.8 vs. 80.7%; P=0.007). The results of a multivariate analysis of overall survival indicated that NOS was a significant independent prognostic factor (hazard ratio, 1.40; 95% confidence interval, 1.02-1.86; P=0.041). These results indicated that pre-operative NOS was significantly associated with poorer survival, including for stage I disease. In conjunction with other clinicopathological parameters, NOS can be a useful prognostic factor when deciding on a treatment strategy for NSCLC.
机译:选择治疗策略时,非小细胞肺癌(NSCLC)的组织学亚型是重要因素。但是,由于不确定的组织学亚型,偶尔会遇到在手术前被诊断为“未另外指定”(NOS)的病例。本研究调查了NOS亚型对可切除NSCLC患者的预后意义。在2001年至2011年之间,日本的两家机构通过经支气管活检诊断为1,913例NSCLC患者,并进行了手术切除。在这些患者中,有151例(7.9%)在术前被诊断为NSCLC-NOS(NOS组),其余患者已确认组织学亚型(确诊组)。本研究比较了这些组的临床病理特征和预后。切除标本的分析显示,NOS组的多形性细胞癌,大细胞神经内分泌细胞癌,大细胞癌和腺鳞癌明显多于确诊组(P <0.001,P = 0.002,P = 0.019和P = 0.014)。 NOS组的五年生存率显着降低(60.5比67.1%; P = 0.010),特别是对于I期疾病(70.8比80.7%; P = 0.007)。总生存期的多变量分析结果表明,NOS是重要的独立预后因素(危险比1.40; 95%置信区间1.02-1.86; P = 0.041)。这些结果表明,术前NOS与较差的存活率显着相关,包括I期疾病。结合其他临床病理参数,NOS在决定NSCLC的治疗策略时可能是有用的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号